RHYTHM PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$40.86 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-11-08
- RHYTHM PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$40.86M.
- RHYTHM PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$45.00M.
- RHYTHM PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$52.76M, a 180.24% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$44.10M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month |
|---|---|---|---|
| 2022-09-30 | -$40.86M 10-Q · filed 2022-11-08 | -$85.86M derived: sum of 2 quarters · filed 2022-11-08 | -$138.63M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$45.00M 10-Q · filed 2022-08-03 | -$97.77M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | -$52.76M 10-Q · filed 2022-05-03 | ||
| 2021-09-30 | -$44.10M 10-Q · filed 2022-11-08 | -$84.51M derived: sum of 2 quarters · filed 2022-11-08 | -$18.76M 10-Q · filed 2022-11-08 |
| 2021-06-30 | -$40.41M 10-Q · filed 2022-08-03 | $25.34M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $65.76M 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | -$33.82M 10-Q · filed 2021-11-02 | -$99.10M 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |